Skip to content
Clinical Trials – home
GermanyBack to Germany

Clinical trials in Hamburg – page 48

1 128 clinical trials in Hamburg, Germany across 19 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

GermanyOur site in GermanyKlinischeStudien.de(opens in a new tab)
Hamburg at a glance
1 128
clinical trials
  • Research sites19
Type of trial
Recruitment status
Quick filters

1 128 trials in Hamburg

Open in trial search

Sjogren's syndrome

Not recruiting

Evaluation of Dazodalibep Efficacy and Safety in Patients with Moderate-to-Severe Sjögren’s Syndrome: A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dazodalibep
  • Sponsor:Horizon Therapeutics Ireland Designated Activity Company

A study testing cagrilintide and semaglutide for heart safety in people with cardiovascular disease

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Testing Drug Combinations with GSK4381562A, GSK6097608, GSK4428859 and Dostarlimab in Patients with PD-L1 Positive Head and Neck Cancer That Has Spread or Returned

Registered drugNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Dostarlimab
  • Sponsor:Glaxosmithkline Research & Development Limited

Sjogren's syndrome

Not recruiting

A Study Testing Imeroprubart for Adults with Primary Sjogren's Disease with Moderate to Severe Symptoms

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:IMEROPRUBART
  • Sponsor:Immunovant Sciences GmbH

Type 2 diabetes mellitus+2

Not recruiting

A Study of Cagrilintide and Semaglutide for Weight Loss in People with Type 2 Diabetes and Overweight or Obesity

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Cagrilintide
  • Sponsor:Novo Nordisk A/S

Cardiac failure

Not recruiting

A study comparing ziltivekimab to placebo in patients with heart failure with mildly reduced or preserved ejection fraction and inflammation

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Ziltivekimab
  • Sponsor:Novo Nordisk A/S

Psoriasis

Not recruiting

Study of zasocitinib (TAK-279) and apremilast compared to placebo in adults with moderate to severe plaque psoriasis

Registered drug
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Apremilast
  • Sponsor:Takeda Development Center Americas Inc.

Dermatitis atopic

Not recruiting

Study of Rocatinlimab Treatment for Adults and Adolescents with Moderate to Severe Atopic Dermatitis

Investigational
Countries:GermanyGermany
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Rocatinlimab
  • Sponsor:Amgen Inc.

Study of Verekitug to improve symptoms in patients with moderate to severe chronic obstructive pulmonary disease (COPD)

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg1 Kappa Monoclonal Antibody Against Crlf2
  • Sponsor:Upstream Bio Inc.

Asthmatic crisis

Not recruiting

Long-term safety and effectiveness study of verekitug injections in adults with severe asthma who completed the VALIANT trial

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Human Igg1 Kappa Monoclonal Antibody Against Crlf2
  • Sponsor:Upstream Bio Inc.

Hidradenitis

Not recruiting

Long-term safety and effectiveness study of sonelokimab injections for patients with moderate to severe hidradenitis suppurativa

InvestigationalNo placebo
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Substances:Sonelokimab
  • Sponsor:MoonLake Immunotherapeutics AG

Hypercholesterolaemia

Not recruiting

Study of AZD0780 in patients with high cholesterol and heart disease or risk of heart disease to lower bad cholesterol levels

Investigational
Countries:GermanyGermany
  • Participants:18–64 years · 65+ years
  • Sponsor:AstraZeneca AB

Other cities in Germany

The busiest research cities in the country

All 516 cities in Germany

Clinical research in Hamburg

What the registry says about research in the country

01 Oncology Research

Current clinical trials focusing on innovative treatments for metastatic prostate cancer, colorectal cancer, and breast cancer. Studies are evaluating new therapeutic combinations and targeted approaches for improved patient outcomes.

  • Advanced cancer therapies
  • Immunotherapy combinations
  • Treatment resistance strategies
02 Infectious Disease Prevention

Comprehensive vaccine development programs targeting respiratory syncytial virus, cytomegalovirus, and meningococcal infections. Research focuses on both adult and pediatric populations.

  • Vaccine immunogenicity
  • Long-term protection
  • Novel vaccine platforms
03 Neurological Conditions

Groundbreaking research in treating acute cerebral ischemic stroke with innovative therapies. Studies are evaluating functional outcomes and safety profiles of new therapeutic agents.

  • Stroke treatment
  • Neuroprotective strategies
  • Recovery outcomes
04 Women's Health

Clinical investigations addressing vaginal atrophy and contraceptive technologies. Research includes novel delivery systems and hormone-based treatments for postmenopausal conditions.

  • Reproductive health
  • Hormone therapy
  • Novel delivery systems
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.